Fred Alger Management’s Milestone Pharmaceuticals MIST Stock Holding History

Fred Alger Management’s Portfolio MIST Stock Details MIST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-26,672	Closed	-$245K	–	548
2022 Q3	$245K	Buy	+26,672	New	+$202K	﹤0.01%	425

Other funds holding MIST

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Fred Alger Management's MIST Position: Q4 2022 in Review

Fred Alger Management sold out of Milestone Pharmaceuticals (MIST) in Q4 2022, closing a stake of 26,672 shares — an estimated $245K sold.

Fred Alger Management first reported a position in MIST in Q3 2022 and held it in 1 quarter. The position peaked at $245K in Q3 2022. 56 funds tracked by Wall St. Rank hold MIST as of Q4 2022.

Fred Alger Management reported no remaining Milestone Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Fred Alger Management sold 26,672 Milestone Pharmaceuticals shares in Q4 2022, an estimated $245K.
Fred Alger Management first reported a position in Milestone Pharmaceuticals in Q3 2022 and held it in 1 quarter.
Fred Alger Management's Milestone Pharmaceuticals position peaked at $245K in Q3 2022.
56 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q4 2022.

Based on Fred Alger Management's 13F filing for Q4 2022, filed 14 Feb 2023.